A Phase I Study of Combination Chemotherapy with Gemcitabine and Oral S-1 for Advanced Pancreatic Cancer-Reference-Cited by-同舟云学术

A Phase I Study of Combination Chemotherapy with Gemcitabine and Oral S-1 for Advanced Pancreatic Cancer

Published:2005 Issue:5 Volume:69 Page:421-427
ISSN:0030-2414
Container-title:Oncology
language:en
Short-container-title:Oncology

Author:

Ueno Hideki,Okusaka Takuji,Ikeda Masafumi,Ishiguro Yoriko,Morizane Chigusa,Matsubara Junichi,Furuse Junji,Ishii Hiroshi,Nagase Michitaka,Nakachi Kohei

Publisher

S. Karger AG

Subject

Cancer Research,Oncology,General Medicine

Reference31 articles.

1. Evans DB, Abbruzzese JL, Willett CG: Cancer of the pancreas; in De Vita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology. Philadelphia, Lippincott-Raven, 2001, pp 1126-1161.

2. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

3. Phase II trial of gemcitabine (2,2?-difiuorodeoxycytidine) in patients with adenocarcinoma of the pancreas

4. Phase II study of gemcitabine in patients with advanced pancreatic cancer

5. Phase III Study of Gemcitabine in Combination With Fluorouracil Versus Gemcitabine Alone in Patients With Advanced Pancreatic Carcinoma: Eastern Cooperative Oncology Group Trial E2297

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase II study of SOXIRI (S-1/oxaliplatin/irinotecan) chemotherapy in patients with unresectable pancreatic ductal adenocarcinoma;Pancreatology;2023-12

2. Phase II Study of SOXIRI (S-1/Oxaliplatin/Irinotecan) Chemotherapy in Patients with Unresectable Pancreatic Ductal Adenocarcinoma: A Prospective Study (Preprint);2022-06-21

3. Phase II Study of the Triple Combination Chemotherapy of SOXIRI (S-1/Oxaliplatin/Irinotecan) in Patients with Unresectable Pancreatic Ductal Adenocarcinoma;The Oncologist;2019-01-24

4. Gemcitabine plus S-1 for metastatic pancreatic cancer;Medicine;2018-10

5. Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma;Cancer Chemotherapy and Pharmacology;2015-12-08